We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28
U.S. Biotech Industry Analysis
UpdatedMay 30, 2023
DataAggregated Company Financials
Companies646
- 7D-3.3%
- 3M-0.6%
- 1Y8.5%
- YTD-2.6%
Over the last 7 days, the Biotech industry has dropped 2.7%, driven by AbbVie declining 5.1%. Meanwhile, Arcus Biosciences actually outperformed within the industry, gaining 21% in the last week. In the past year, the industry has gained 8.5%. Looking forward, earnings are forecast to grow by 22% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 30 May 2023 | US$1.1t | US$185.9b | -US$16,045,777,796.00 | 11.2x | -69.9x | 6x |
| Thu, 27 Apr 2023 | US$1.2t | US$198.5b | -US$3,096,107,692.00 | 12.8x | -375.3x | 5.9x |
| Sat, 25 Mar 2023 | US$1.1t | US$199.3b | -US$3,645,756,952.00 | 13.4x | -310.8x | 5.7x |
| Mon, 20 Feb 2023 | US$1.2t | US$202.6b | -US$64,851,937.00 | 16.5x | -17789.6x | 5.7x |
| Wed, 18 Jan 2023 | US$1.2t | US$203.6b | US$1.7b | 14.6x | 683.1x | 5.8x |
| Fri, 16 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.5x | 734.9x | 5.7x |
| Sun, 13 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.6x | 1045.5x | 5.5x |
| Tue, 11 Oct 2022 | US$1.0t | US$205.9b | US$5.4b | 14.9x | 192.3x | 5x |
| Thu, 08 Sep 2022 | US$1.0t | US$206.1b | US$6.0b | 14.5x | 169.1x | 5x |
| Sat, 06 Aug 2022 | US$1.1t | US$211.4b | US$8.8b | 16.7x | 125.7x | 5.3x |
| Mon, 04 Jul 2022 | US$1.1t | US$212.1b | US$11.0b | 15.8x | 95.4x | 5x |
| Wed, 01 Jun 2022 | US$1.0t | US$212.7b | US$11.2b | 15.2x | 89.5x | 4.7x |
| Fri, 29 Apr 2022 | US$1.1t | US$200.2b | US$8.5b | 17.2x | 123.1x | 5.2x |
| Sun, 27 Mar 2022 | US$1.3t | US$221.9b | US$11.4b | 18.9x | 111.3x | 5.7x |
| Tue, 22 Feb 2022 | US$1.2t | US$216.5b | US$5.6b | 21.8x | 216.6x | 5.6x |
| Thu, 20 Jan 2022 | US$1.3t | US$212.0b | US$2.5b | 23.2x | 505x | 5.9x |
| Sat, 18 Dec 2021 | US$1.5t | US$211.9b | US$3.1b | 26.1x | 466.7x | 6.9x |
| Mon, 15 Nov 2021 | US$1.5t | US$212.2b | US$3.9b | 27.1x | 376.7x | 6.9x |
| Wed, 13 Oct 2021 | US$1.5t | US$196.3b | -US$2,605,456,444.00 | 23.3x | -557.7x | 7.4x |
| Fri, 10 Sep 2021 | US$1.6t | US$196.4b | -US$2,275,254,373.56 | 21.1x | -695.3x | 8.1x |
| Sun, 08 Aug 2021 | US$1.6t | US$197.0b | -US$1,525,228,785.58 | 23.2x | -1033.1x | 8x |
| Sat, 01 May 2021 | US$1.4t | US$174.8b | -US$11,096,405,382.55 | 22.2x | -127.4x | 8.1x |
| Tue, 02 Feb 2021 | US$1.4t | US$162.7b | -US$10,894,429,089.90 | 19x | -128.8x | 8.6x |
| Fri, 06 Nov 2020 | US$1.1t | US$150.4b | -US$4,980,288,109.88 | 20.1x | -223.3x | 7.4x |
| Mon, 10 Aug 2020 | US$1.1t | US$138.5b | -US$5,301,501,654.29 | 21.5x | -212.2x | 8.1x |
Price to Earnings Ratio
-183.1x
Current Industry PE
- Investors are pessimistic on the American Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.8x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 23% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does U.S. Biotech compare with similar industries?
| US Market | 0.061% | |
| Healthcare | -2.95% | |
| Biotech | -3.29% | |
| Biotech | -3.29% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RCUS Arcus Biosciences | US$22.03 | 22.0% +US$291.0m | 16.3% | PS13.5x | |
| ZNTL Zentalis Pharmaceuticals | US$30.05 | 12.4% +US$196.9m | 24.6% | PB4.6x | |
| KDNY Chinook Therapeutics | US$23.31 | 8.2% +US$118.4m | 53.6% | PS296.5x | |
| VSTM Verastem | US$1.01 | 120.4% +US$110.8m | -21.1% | PB6.1x | |
| APLS Apellis Pharmaceuticals | US$86.97 | 1.0% +US$102.5m | 109.8% | PS95.7x |